Merck & Co., Inc.

Keytruda is prescribed for ongoing cancer treatment across more than 40 indications, creating a large quasi-recurring patient cohort, and FY2025 Keytruda sales of $31.7 billion reflected continued stable demand. Forward visibility narrows materially toward 2028 as patent expiration and IRA price-setting events approach, and no contractual backlog underpins the revenue.

Keytruda and Keytruda Qlex represented approximately 49% of total FY2025 revenue, and the pharmaceutical segment accounted for 89% of company-wide sales, with Animal Health at $6.4 billion as the only meaningful secondary business. Gardasil and Winrevair add breadth within pharma, but a single product above 40% of revenue represents a structural concentration.

The United States generated 56.2% of FY2025 revenue, up from 50.3% in FY2024 after Gardasil shipments into China were halted and China's contribution fell from 8.6% to 3.0% in a single year. EMEA (22.4%), Latin America (5.3%), and Asia Pacific (4.6%) provide real but not balancing international exposure.

Branded pharmaceutical drugs carry high gross margins with low incremental cost per additional dose sold, but Merck reinvests heavily in R&D to sustain its pipeline, structurally limiting consolidated operating leverage. Scale economics exist within approved products but are not software-like, given the manufacturing and global sales infrastructure required.

Keytruda addresses life-threatening cancers across more than 40 approved indications, creating repeat demand over multi-month treatment courses with high mission-criticality in clinical practice. Animal Health revenues are similarly recurring through ongoing veterinary protocols, and neither stream is contractual but both sit at the higher-quality end of the transactional spectrum.